Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune Response to Intradermal Influenza Vaccination
NCT07908329Phase 1Recruiting
- Sponsor
- Yale University
- Start
- Oct 2026
- Primary completion
- May 2029
- Countries
- 1
01
Overview
Phase 1, open-label trial of Fluzone Trivalent in influenza (3 arms), sponsored by Yale University. Primary endpoints: Change in antibody titer concentration to vaccination-Blood at Day 28 and Change in antibody titer concentration to vaccination-Skin at Day 28. Started Oct 2026; status: recruiting.
02
Drugs
Fluzone Trivalent
03
Conditions
influenza
Beyond the preview
Go deeper on NCT07908329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07908329.